Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa (PIONEER (OLE))

This study has been completed.
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) ) Identifier:
First received: March 2, 2012
Last updated: September 26, 2016
Last verified: September 2016
Hidradenitis Suppurativa is a painful, chronic skin disease characterized by recurrent inflamed nodules and abscesses, which may rupture to form fistulas and subsequent scarring. This Study is an open-label extension study available to subjects who participated in a prior adalimumab study who meet all the inclusion and none of the exclusion criteria. The purpose of this study to evaluate the long term safety, tolerability and efficacy of adalimumab in subjects with moderate to severe HS.

Condition Intervention Phase
Hidradenitis Suppurativa
Biological: Adalimumab
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension)

Resource links provided by NLM:

Further study details as provided by AbbVie:

Primary Outcome Measures:
  • Proportion of subjects achieving clinical response [ Time Frame: Baseline (Week 0) up to Week 60 ] [ Designated as safety issue: No ]
    Subjects achieving improvement in hidradenitis suppurativa severity

Enrollment: 510
Study Start Date: April 2012
Study Completion Date: August 2016
Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: adalimumab Biological: Adalimumab
Prefilled syringe of adalimumab
Other Name: Humira

Detailed Description:
The purpose of this study to evaluate the long term safety, tolerability and efficacy of adalimumab in subjects with moderate to severe HS. The clinical trial identifier is PIONEER (OPEN-LABEL EXTENSION).

Ages Eligible for Study:   18 Years to 99 Years   (Adult, Senior)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects who previously participated in a prior Phase 3 Abbott HS study and:

    1. Completed the study; or
    2. Experienced a loss of response (LOR); or
    3. Experienced Worsening or Absence of Improvement

      Exclusion Criteria:

  • Prior treatment with any other anti-TNF therapy (e.g., infliximab, etanercept), or participation in an adalimumab trial other than a prior Phase 3 Abbott HS study.
  • Subject received any oral antibiotic treatment for HS within 28 days prior to the Baseline visit, except for antibiotics permitted in a prior Phase 3 Abbott HS study.
  • Subject received oral concomitant analgesics (including opioids) for HS-related pain within 14 days prior to the Baseline visit, except for permitted analgesics taken in the prior Phase 3 Abbott HS study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01635764

  Show 96 Study Locations
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Study Director: Dawn Carlson, MD AbbVie
  More Information

Additional Information:
Responsible Party: AbbVie (prior sponsor, Abbott) Identifier: NCT01635764     History of Changes
Other Study ID Numbers: M12-555  2011-003478-98 
Study First Received: March 2, 2012
Last Updated: September 26, 2016
Health Authority: Czech Republic: State Institute for Drug Control
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Canada: Health Canada
Australia: Department of Health and Ageing Therapeutic Goods Administration
Germany: Paul-Ehrlich-Institut
Turkey: Ministry of Health
Hungary: National Institute of Pharmacy
Denmark: Danish Medicines Agency
United States: Food and Drug Administration
Sweden: Medical Products Agency
Greece: National Organization of Medicines
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Switzerland: Swissmedic

Keywords provided by AbbVie:
hidradenitis suppurativa
acne inversa
tumor necrosis factor

Additional relevant MeSH terms:
Hidradenitis Suppurativa
Skin Diseases, Bacterial
Bacterial Infections
Skin Diseases, Infectious
Skin Diseases
Sweat Gland Diseases
Anti-Inflammatory Agents
Antirheumatic Agents processed this record on January 17, 2017